Mélanie ROBERT
|
Education: ♦ 2014: Master of science degree in Biotechnology, University of Montpellier 2. ♦ 2012: Bachelor of science degree in Biology Professional experience : ♦ October 2017 - March 2018: ERYTECH Pharma / LIBM Laboratory, Lyon - Associate research scientist Multiparametric characterization of red blood cells after an hypotonic dialysis based drug encapsulation process. ♦ October 2016 - April 2017: IMAXIO, Lyon - Biochemical engineer Processes development for the production and purification of recombinant protein. Physico-chemical characterization of proteins. ♦ CEA, Marcoule - Biochemical engineer Processes development for the production and purification of two recombinant domain of fetuin. ♦ February - August 2014: PX’THERAPEUTICS ,Grenoble - Biochemical engineer, Internship Processes development for the production and purification of four recombinant protein in E.coli. ♦ November 2012 - April 2013: NOSOPHARM, Nîmes - Engineer assistant, Internship,
|
Mélanie Robert (melanie.robert @ univ-lyon1.fr)
Nationality: French Institution Université Claude Bernard (Lyon 1) Team: [VBRBC] Position: PhD student
Publications
|
Title: Technical development for the characterization of red blood cells after an hypotonic-dialysis based drug encapsulation process. (Summary) Goal: Characterize the impact of ERYCAPS® technology, an Erytech Pharma technology enabling the drug encapsulation inside red blood cells (RBC), on the RBC properties. Supervisor: Philippe Connes Co-supervisor: Philippe Joly - Agnès Cibliel (Erytech Pharma) Funding: Erythec Pharma Start: 04/2018 End expected: 07/2021
| |
1. Robert M. et al. - International Journal of Molecular Sciences (2020) - Impact of Trail Running Races on Blood Viscosity and Its Determinants: Effects of Distance. 2. Robert M. et al. - Eur. J. Appl. Physiol (2019) - Impact of a 10 km running trial on eryptosis, red blood cell rheology, and electrophysiology in endurance trained athletes: a pilot study. 3. Robert M. et al. - Arch. Toxicol (2019 - Deciphering the uranium target proteins in human dopaminergic SH-SY5Y cells. | |
